文献速递哮喘

气道自身抗体是哮喘严重程度的决定因素

Airway autoantibodies are determinants of asthma severity.
PubMed 文献 · Eur Respir J · 2022-12-01

该研究分析148例哮喘患者218份痰标本,检测抗EPX、抗MARCO及抗核抗体等气道自身抗体。55%患者存在≥2种气道自身反应(CAAS+),且与痰嗜酸性粒细胞脱颗粒、血白细胞升高及淋巴细胞降低相关。CAAS+患者中三分之一报告急性加重,抗炎治疗不能减弱气道自身抗体。

要点

  • 55%中重度哮喘患者存在气道自身反应,抗炎治疗不能减弱。
  • 气道自身反应与痰嗜酸性粒细胞脱颗粒及血白细胞升高相关。
  • CAAS+患者中三分之一报告急性加重,与抗EPX/抗MARCO IgG升高相关。

核心结论

  • 55%中重度哮喘患者存在气道自身反应,尽管接受抗炎治疗仍持续存在,并与急性加重相关。
  • 气道自身抗体是哮喘严重程度的决定因素。

研究设计与样本

  • 前瞻性分析148例哮喘患者218份痰标本,检测抗EPX、抗MARCO及抗核抗体。
  • 评估自身抗体与肺功能、血/气道炎症、严重程度指数及急性加重的关联。
  • 107例患者填写自身免疫检查表以确定个人/家族系统性自身免疫病史。

主要发现

  • 148例中59例(40%)抗EPX IgG+,53例(36%)抗MARCO IgG+,129例中64例(50%)有≥2种核/核外自身反应。
  • 82例(55%)有≥2种气道自身反应(CAAS+)。
  • 气道嗜酸性粒细胞脱颗粒增加(OR 15.1,95%CI 1.1-199.4)、血白细胞增加(OR 3.5,95%CI 1.3-10.1)和血淋巴细胞减少(OR 0.19,95%CI 0.04-0.84)预测CAAS+。
  • 三分之一CAAS+患者报告急性加重,与抗EPX和/或抗MARCO IgG升高相关(p<0.05)。
  • 30% CAAS+哮喘患者报告干燥症状(p=0.02),家族史或个人自身免疫病诊断与CAAS+无关联。

临床怎么用

  • 对中重度哮喘患者,应考虑气道自身反应作为持续加重和严重程度的潜在机制。
  • 抗炎治疗不能减弱气道自身抗体,提示需针对自身免疫机制的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local airway autoimmune responses may contribute to steroid dependence and persistent eosinophilia in severe asthma. Auto-IgG antibodies directed against granule proteins such as eosinophil peroxidase (EPX), macrophage scavenger receptor with collagenous structure (MARCO) and nuclear/extranuclear antigens (antinuclear antibodies (ANAs)) have been reported. Our objective was to describe the prevalence and clinical characteristics of asthmatic patients with airway autoreactivity, and to assess if this could be predicted from clinical history of autoreactivity. METHODS: We analysed anti-EPX, anti-MARCO and ANAs in 218 sputum samples collected prospectively from 148 asthmatic patients, and evaluated their association with lung function parameters, blood/airway inflammation, severity indices and exacerbations. Additionally, 107 of these patients consented to fill out an autoimmune checklist to determine personal/family history of systemic autoimmune disease and symptoms. RESULTS: Out of the 148 patients, 59 (40%) were anti-EPX IgG+, 53 (36%) were anti-MARCO IgG+ and 64 out of 129 (50%) had ≥2 nuclear/extranuclear autoreactivities. A composite airway autoreactivity score (CAAS) demonstrated that 82 patients (55%) had ≥2 airway autoreactivities (considered as CAAS+). Increased airway eosinophil degranulation (OR 15.1, 95% CI 1.1-199.4), increased blood leukocytes (OR 3.5, 95% CI 1.3-10.1) and reduced blood lymphocytes (OR 0.19, 95% CI 0.04-0.84) predicted CAAS+. A third of CAAS+ patients reported an exacerbation, associated with increased anti-EPX and/or anti-MARCO IgG (p<0.05). While no association was found between family history or personal diagnosis of autoimmune disease, 30% of CAAS+ asthmatic patients reported sicca symptoms (p=0.02). Current anti-inflammatory (inhaled/oral corticosteroids and/or adjunct anti-interleukin-5 biologics) treatment does not attenuate airway autoantibodies, irrespective of eosinophil suppression. CONCLUSION: We report 55% of moderate-severe asthmatic patients to have airway autoreactivity that persists despite anti-inflammatory treatment and is associated with exacerbations.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Salter, Zhao, Son, et al. Airway autoantibodies are determinants of asthma severity. Eur Respir J. 2022. PMID: 35777765. doi:10.1183/13993003.00442-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。